The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Bradley G. Somer
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Chung-Pin Li
No relevant relationships to disclose
Max E. Scheulen
Research Funding - GlaxoSmithKline
Saifuddin M. Kasubhai
No relevant relationships to disclose
Do-Youn Oh
No relevant relationships to disclose
Yuan Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Soumi Lahiri
Employment or Leadership Position - GlaxoSmithKline
Klaudia Steplewski
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ngocdiep T. Le
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline